



NDA 22327/S-022

**SUPPLEMENT APPROVAL**

Novartis Consumer Health, Inc  
Attention: Marie C. Vicinanza, MS, RD  
Associate Director, US Regulatory Affairs  
200 Kimball Drive  
Parsippany, NJ 07054-0622

Dear Ms. Vicinanza:

Please refer to your supplemental New Drug Application (sNDA) received January 12, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Prevacid 24HR (lansoprazole) delayed release capsules, 15 mg.

We acknowledge receipt of your amendments dated February 17, March 3, and May 8, 2015. We also reference our October 31, 2014 CBE-0 supplement request letter.

This "Changes Being Effected" sNDA provides for changes to the carton and Drug Facts label to include the addition of the following label warnings requested in the October 31, 2014 CBE-0 supplement request letter:

Under the Drug Facts Warnings heading "**Ask a doctor or pharmacist before use if you are taking**", adding the new bulleted statement:

- methotrexate (arthritis medicine)

and by revising the existing immunosuppressant drug interaction warning by adding mycophenolate mofetil:

- tacrolimus or mycophenolate mofetil (immune system medicines).

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

**LABELING**

Submit final printed labeling (FPL) for Prevacid 24HR (lansoprazole) delayed release capsules, as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the Consumer Information Leaflet submitted January 12, 2015, the 14-count immediate container (bottle) label, the 14-, 28- and 42-count cartons and the 42-count "Club

Pack” carton labels submitted February 17, 2015, and the 42-count “Bonus” carton submitted May 8, 2015.

The FPL should be submitted electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 22327/S-022.**” Approval of this submission by FDA is not required before the labeling is used.

Please submit one market package of the drug product when it is available.

If sending via USPS, please send to:

Mr. Jeffrey Buchanan  
Food and Drug Administration  
Center for Drug Evaluation and Research  
White Oak Building 22, Room: 5461  
10903 New Hampshire Avenue  
Silver Spring, Maryland 20993

If sending via any carrier other than USPS  
(e.g., UPS, DHL), please send to:

Mr. Jeffrey Buchanan  
Food and Drug Administration  
Center for Drug Evaluation and Research  
White Oak Building 22, Room: 5461  
10903 New Hampshire Avenue  
Silver Spring, Maryland 20903

## **DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call CAPT Janice Adams-King, Safety Regulatory Project Manager, at (301) 796-3713.

Sincerely,

*{See appended electronic signature page}*

Valerie Pratt, M.D.  
Acting Deputy Director for Safety  
Division of Nonprescription Drug Products  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research

ENCLOSURES:  
Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

VALERIE S PRATT  
06/30/2015